Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women

Arkopharma

Status and phase: Unknown; Phase 3

Conditions: Postmenopause

Treatments: Drug: soy isoflavone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00235924

PHY04GE01

Details and patient eligibility

About

The main objective of this study is to determine the effects on the endometrium and breast of 70 mg daily dose of isoflavones.

Full description

This is an international multicentre open study, assessing the innocuity on breast and endometrium of a 70 mg daily dose of isoflavones standardized extract (Phytosoya).

This study follows the European guidelines :one-year treatment duration, biopsy and mammography performed at the beginning and at the end of the trial, recruitment of enough subjects in order to have 300 patients with an evaluable biopsy after one year of treatment.

After 3 weeks of screening phase, the patients will be taken Phytosoya during 52 weeks. At the end of the first year of treatment, an endometrial biopsy, an endovaginal ultrasonography, a mammography, breast ultrasounds, a clinical examination and a biological assessment will be performed.

In addition, it will be proposed to patients to continue treatment during 2 additional years. At the end of the third year,the same examinations will be performed.

Sex: Female

Ages: 45 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Not hysterectomised women
• Post menopausal (at least 2 years)
• FSH superior to 30 UI/l and oestradiol inferior to 35 ng/ml
• Presenting with hot flushes (but not incapacitating) or climacteric symptoms

Exclusion criteria

• History of endometrial hyperplasia
• Known hormono-dependent malignant tumours
• BMI superior to 30 Kg/m2
• Uncontrolled arterial hypertension
• Known renal or liver insufficiency
• Recent or evolutive thromboembolic disease
• Unexplained bleeding, endometrial polyps, submucous myomas, active endometriosis, ovarian cyst superior to 30 mm
• Local hormonal treatment, raloxifene,tibolone within the 3 months before V1 and during the study
• HRT and DHEA within the 3 months before V2 and during the study
• isoflavones within the 2 months before V2 and during the study
• clonidine, beta-alanine, veralipride within 1 month before V1 and during the study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)